Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?
ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
What's Your Reaction?
